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host defenses against microbial infec-
tion, inflammation, and injury (Ouyang,
2010). Increasing IL-22R expression in
keratinocytes by IFN-a may be one of
the defense systems of injured skin.
Damage causes infiltration of pDCs,
which are activated by self-nucleic acid
derived from damaged keratinocytes or
other cells via Toll-like receptors 7 and
9, producing IFN-a/b (Gregorio et al.,
2010). Although the detailed mechan-
isms remain unclear, IFN-a/b produced
by pDCs influences IL-17- and IL-22-
producing T cells by activation of
myeloid dendritic cells (Gregorio
et al., 2010). IL-22 signals via IL-22R
inhibit keratinocyte terminal differen-
tiation, causing thickening of the
epidermis (Sa et al., 2007). IL-22 also
induces production of heparin-binding
epidermal growth factor-like growth
factor from keratinocytes and may
mediate the proliferation of the epider-
mis (Sa et al., 2007; Tohyama et al.,
2009). Moreover, IL-22 induces expres-
sion of several genes in keratinocytes,
such as human b-defensin 2 and S100
family genes, that are antimicrobial
proteins (Wolk et al., 2006; Ouyang,
2010). Although these cellular responses
will usually become downregulated after
the repair of injury, the responses may
trigger the development of lesions in
psoriasis. Further studies will be neces-
sary to clarify this mechanism.
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TO THE EDITOR
Significant advances in the understand-
ing of the biology and molecular
mechanisms of cancer have allowed
the development of new targeted agents
for the treatment of melanoma. Pre-
vious studies showed that BRAF and
NRAS mutations were observed in
approximately 40–60% and 15–20% of
cutaneous melanomas (Chapman et al.,
2011; Lee et al., 2011), respectively.
Most of the data regarding genetic
mutations associated with melanomas
have been obtained from Caucasian
cohorts, and comprehensive screenings
of the Chinese population are limited.
In this study, we examined the mutation
profiles using the MassARRAY System
(Sequenom, San Diego, CA) to deter-
mine the prevalence of oncogene
mutations in melanoma patients from
southern China.
The MassARRAY platform provides
a superior technology for the screening
of 238 hot-spot cancer mutations in
19 common oncogenes: ABL1, AKT1,
AKT2, BRAF, CDK4, EGFR, ERBB2,
FGFR1, FGFR3, FLT3, JAK2, KIT, MET,
HRAS, KRAS, NRAS, PDGFRA, PIK3CA,
and RET (Supplementary Table S1 on-
line). A total of 114 formalin-fixed and
paraffin-embedded melanoma lesions
were examined: 28 paired primary acral
melanomas with corresponding lymph
node metastasis; 28 mucosal melano-
mas; and 30 non-chronic sun-induced
damage melanomas (Supplementary
Table S2–4 online). The study protocol
was approved by the research ethics
committee of Sun Yat-Sen University
Cancer Center, China.
At least one mutation was detected in
33 of the 86 (38.4%) melanomas, with
mutations observed in BRAF (16.3%),
NRAS (10.5%), KIT (5.8%), EGFR
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(4.7%), HRAS (2.3%), KRAS (2.3%),
MET (2.3%), and PIK3CA (1.2%). All
detected mutations were validated
by direct sequencing (Supplementary
Table S5 online). Compared with that
in Caucasian cohorts, the mutation rate
of BRAF is low in Chinese melanoma
cases; a similar result was obtained by
Qi et al. (2011). With regard to the
mutation rates of KIT in northern and
southern Chinese patients, the latter
showed a lower frequency (Kong et al.,
2011). One possible explanation for
differences between our results and
those of Kong et al. is that some hot-
spots covered in the study by Kong et al.
are not included in mutation profiles of
the MassARRAY System.
EGFR mutation was documented in
1 of 238 melanomas in the COSMIC
(the Catalog of Somatic Mutations in
Cancer) database. In the present study,
EGFR mutations were observed in 3 of
28 (10.7%) acral melanomas (EGFR
T790M and EGFR L861Q) and in 1 of
28 (3.6%) mucosal melanomas (EGFR
E749-A750del). Interestingly, three of
four cases with EGFR mutations
were concurrent with other mutations
(Table 1), and these relationships would
complicate the response of melanomas
to EGFR inhibitors (Patel et al., 2011).
Currently, it remains unclear how co-
occurring mutations arise. In many
cases, mutations in a single gene in
one signaling pathway cannot signifi-
cantly affect cellular signaling, and
accumulated mutations in the activated
signaling pathway tend to amplify the
effects of cancer gene mutations and
have significant influences on the dys-
function of the signaling pathway. These
co-occurring mutations may therefore
function synergistically in tumor forma-
tion and development (Cui, 2010).
Although most patients who undergo
targeted therapy are diagnosed at an
advanced stage with metastases, the
mutation status is routinely analyzed
using primary tumors. Given the het-
erogeneity of malignant carcinoma at
the molecular level, we examined the
discrepancy in oncogenic mutations
between primary tumors and the corre-
sponding lymph node metastases. Of
28 patients, 17 (60.7%) with wild-type
status in the primary tumor lacked a
mutation in the corresponding lymph
node. In all, 11 of 28 patients (39.3%)
had mutations in the primary tumors
and 8 (28.6%) had mutations in the
metastatic lymph nodes, respectively.
Of those 11 patients with mutations in
the primary tumor, 5 patients (45.5%)
had concordant mutations in the meta-
static lymph nodes, and 3 patients
(27.3%) had mutations only in the
primary tumors. Furthermore, two pa-
tients (18.2%) had co-occurring muta-
tions in the primary tumors and only a
single mutation in the metastatic lymph
nodes. One patient (9.1%) presented
with two completely different muta-
tions between the primary tumor and
the metastatic lymph node (Table 2).
Our results demonstrated that mela-
noma cells that metastasize to the
lymph nodes do not always carry the
same mutations as the primary tumors.
However, the molecular basis of me-
tastasis is still unclear. Two major
models of tumor progression and me-
tastasis, the linear progression model
and the parallel progression model, are
applicable in melanoma progression.
The concordant mutation status be-
tween primary tumors and metastatic
lymph nodes suggests that, in some
melanoma cases, genetic mutations
occur before the tumor metastasizes,
Table 1. Co-occurring mutations in melanomas
Case Gene Mutation
Non-CSD 3 NRAS Q61K
BRAF V600E
Mucosal 1 KIT K558_E562del
EGFR E746_A750del
Mucosal 11 KIT D816Y
MET Y1230C
NRAS G12A
Acral 27 MET R970C
EGFR L861Q
Acral 28 NRAS G12C
EGFR T790M
Abbreviation: Non-CSD, non-chronic sun-induced damage.
Table 2. Mutations in primary acral melanomas and matched lymph node
metastases
Case no. Primary acral melanomas Lymph node metastases
Acral 2 BRAF V600E BRAF V600E
Acral 5 HRAS Q61K
Acral 8 BRAF V600E BRAF V600E
Acral 10 NRAS Q61L NRAS Q61L
Acral 12 BRAF V600E
Acral 13 BRAF V600E BRAF V600E
Acral 19 KRAS G12D
Acral 20 KIT L576P KIT L576P
Acral 24 EGFR L861Q AKT rs11555435
Acral 27 EGFR L861Q EGFR L861Q
MET R970C
Acral 28 NRAS G12C NRAS G12C
EGFR 790M
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and these mutations are then preserved
through the subsequent stages of tumor
development, and no selection occurs
during metastasis. Such observations
have also been reported for lung cancer
cases (Chang et al., 2011). This is in
agreement with the concept of the
linear progression model (Klein, 2009).
The discordant mutation status between
primary tumors and metastatic lymph
nodes suggests that metastasis is a
relatively early event in tumor progres-
sion, and the primary and metastatic
tumors evolve independently according
to the different environments, as re-
ported by Schmidt-Kittler et al. (2003)
in breast cancer cases. This discordance
is consistent with the parallel progres-
sion model (Klein, 2009; Chang et al.,
2011; Han et al., 2011). However,
because the specimens contain a mix-
ture of tumor and normal cells, it
cannot be ruled out that the mutations
that we observed in the primary tumors
are already present in a minor fraction
of tumor cells in the metastatic lymph
nodes that we could not detect in the
analysis.
The mutation prevalence in melano-
ma susceptibility genes may vary within
each specific geographical area (Casula
et al., 2009). In this study, we demon-
strated that there is a tendency for
oncogene mutations in southern Chi-
nese melanoma cases to occur infre-
quently, but with BRAF, NRAS, KIT,
and EGFR mutations being the most
frequent. The observed discordance in
the mutation status between the pri-
mary melanomas and the metastatic
lymph nodes implies that caution
must be taken when therapeutic deci-
sions are based solely on the biological
properties of the primary tumor.
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